Literature DB >> 20615442

Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum.

Wayne A Cass1, Laura E Peters.   

Abstract

Neurturin (NTN), a member of the glial cell line-derived neurotrophic factor (GDNF) family, has substantial effects on normal and lesioned nigrostriatal dopamine systems. However, its ability to protect against toxin-induced loss of striatal dopamine release has not been previously reported. The goal of the present study was to determine if NTN could protect against 6-hydroxydopamine (6-OHDA)-induced reductions in striatal dopamine overflow and tissue levels of dopamine and to compare the effects of NTN with those of GDNF. Male Fischer-344 rats were given a single injection of vehicle, or 5 microg NTN or GDNF, into the right striatum. The following day the animals were given a single injection of 12 microg 6-OHDA into the striatum at the same site where the trophic factor was injected. Microdialysis experiments conducted three weeks later indicated that the 6-OHDA decreased basal levels of dopamine and metabolites in the lesioned striatum compared to the contralateral striatum, and NTN was able to partially protect against the 6-OHDA-induced reductions. Injection of NTN one day prior to 6-OHDA also led to significant protection against loss of both potassium- and amphetamine-evoked overflow of dopamine. The NTN treatments partially protected against 6-OHDA-induced reductions in striatal tissue levels of dopamine and completely protected against loss of nigral dopamine content. The protective effects of NTN were similar in magnitude to those of GDNF. These results support that within the experimental parameters used in this study, NTN is as effective as GDNF in protecting against the dopamine-depleting effects of intrastriatal 6-OHDA. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20615442      PMCID: PMC2934888          DOI: 10.1016/j.neuint.2010.06.019

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  60 in total

1.  In vivo microdialysis studies on somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF.

Authors:  A F Hoffman; C G van Horne; S Eken; B J Hoffer; G A Gerhardt
Journal:  Exp Neurol       Date:  1997-09       Impact factor: 5.330

2.  Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

Authors:  Jeffrey H Kordower; Christopher D Herzog; Biplob Dass; Roy A E Bakay; James Stansell; Mehdi Gasmi; Raymond T Bartus
Journal:  Ann Neurol       Date:  2006-12       Impact factor: 10.422

3.  c-jun expression in substantia nigra neurons following striatal 6-hydroxydopamine lesions in the rat.

Authors:  R Jenkins; R O'Shea; K L Thomas; S P Hunt
Journal:  Neuroscience       Date:  1993-03       Impact factor: 3.590

4.  Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats.

Authors:  A D Smith; D A Kozlowski; M C Bohn; M J Zigmond
Journal:  Exp Neurol       Date:  2005-06       Impact factor: 5.330

5.  GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET.

Authors:  J Opacka-Juffry; S Ashworth; S P Hume; D Martin; D J Brooks; S B Blunt
Journal:  Neuroreport       Date:  1995-12-29       Impact factor: 1.837

6.  GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine.

Authors:  J L Tseng; E E Baetge; A D Zurn; P Aebischer
Journal:  J Neurosci       Date:  1997-01-01       Impact factor: 6.167

7.  Quantitative analyses of GFRalpha-1 and GFRalpha-2 mRNAs and tyrosine hydroxylase protein in the nigrostriatal system reveal bilateral compensatory changes following unilateral 6-OHDA lesions in the rat.

Authors:  D A Kozlowski; E A Miljan; E G Bremer; C G Harrod; C Gerin; B Connor; D George; B Larson; M C Bohn
Journal:  Brain Res       Date:  2004-08-06       Impact factor: 3.252

8.  Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra.

Authors:  Michael F Salvatore; Jin-Lu Zhang; Delia M Large; Patsy E Wilson; Clelland R Gash; Theresa Currier Thomas; John W Haycock; Guoying Bing; John A Stanford; Don M Gash; Greg A Gerhardt
Journal:  J Neurochem       Date:  2004-07       Impact factor: 5.372

9.  Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum.

Authors:  S Kobayashi; S O Ogren; B J Hoffer; L Olson
Journal:  Exp Neurol       Date:  1998-12       Impact factor: 5.330

10.  Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.

Authors:  Christopher D Herzog; Biplob Dass; James E Holden; James Stansell; Mehdi Gasmi; Mark H Tuszynski; Raymond T Bartus; Jeffrey H Kordower
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

View more
  3 in total

1.  ser31 Tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion.

Authors:  Michael F Salvatore
Journal:  J Neurochem       Date:  2014-01-27       Impact factor: 5.372

2.  Neurturin overexpression in dopaminergic neurons induces presynaptic and postsynaptic structural changes in rats with chronic 6-hydroxydopamine lesion.

Authors:  David Reyes-Corona; Nallely Vázquez-Hernández; Lourdes Escobedo; Carlos E Orozco-Barrios; Jose Ayala-Davila; Mario Gil Moreno; Miriam E Amaro-Lara; Yazmin M Flores-Martinez; Armando J Espadas-Alvarez; Manuel A Fernandez-Parrilla; Juan A Gonzalez-Barrios; M E Gutierrez-Castillo; Ignacio González-Burgos; Daniel Martinez-Fong
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

3.  Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson's Disease.

Authors:  Jamileh Ghalami; Tourandokht Baluchnejad Mojarad; Monireh Mansouri; Safoura Khamse; Mehrdad Roghani
Journal:  Basic Clin Neurosci       Date:  2021-01-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.